ROS-scavenging Amino Acid-derived Lipids for the Prevention and Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer

Recruiting now · Not applicable

Conditions studied: Radiation Dermatitis

In brief

Radiation dermatitis is a common complication in head and neck squamous cell carcinoma patients receiving radiotherapy. This study proposes an ROS-scavenging amino acid-based nanolipid to prevent oxidative skin damage. A multicenter randomized trial will evaluate its safety and efficacy in reducing dermatitis severity and improving treatment continuity.

Key facts

Study ID

NCT07081074

Run by

West China Hospital

People needed

40

Starts

2025-07-23

Expected to finish

2026-12-23

Last updated by the study team

2026-04-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a pathological diagnosis of non-metastatic head and neck malignant tumors;
• Patients deemed suitable for high-dose radiotherapy, either as a primary treatment or as postoperative treatment following surgical resection.

You may not qualify if…

• Eastern Cooperative Oncology Group performance status of >2;
• Pre-existing skin rash, ulceration or open wound in the treatment area;
• Known allergy to trolamine or amino acid;
• Inflammatory or connective tissue disorder of the skin;
• History of head and neck radiotherapy.

Where it is running

• West China Hospital, Sichuan University — Chengdu, Sichuan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.